Pharmacokinetic interaction between SHR2554 and fluconazole: A single-center, open-label and one-sequence crossover phase I trial in healthy Chinese subjects

SHR2554, a highly selective oral EZH2 inhibitor, shows promise in treating hematologic malignancies. However, its metabolism via CYP3A4 raises concerns about drug-drug interactions. This study evaluates the impact of fluconazole, a moderate CYP3A4 inhibitor, on the pharmacokinetics and safety implic...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of pharmaceutical sciences Vol. 212; p. 107163
Main Authors:	Dai, Yuyang, Hu, Minwan, Guo, Shaojie, Wu, Feng, Han, Ying, Ni, Siyang, Li, Shaorong, Zhu, Zhenyu, Yuan, Weilan, Zhao, Xiuli
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 01.09.2025
Subjects:	Adult Antifungal Agents - administration & dosage Antifungal Agents - pharmacokinetics Area Under Curve Cross-Over Studies CYP3A4 Cytochrome P-450 CYP3A - metabolism Cytochrome P-450 CYP3A Inhibitors - administration & dosage Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Drug Interactions Drug-drug interaction East Asian People EZH2 inhibitor Female Fluconazole Fluconazole - administration & dosage Fluconazole - adverse effects Fluconazole - pharmacokinetics Fluconazole - pharmacology Healthy Volunteers Humans Male SHR2554 Young Adult SHR2554 Fluconazole Drug-drug interaction CYP3A4 EZH2 inhibitor
ISSN:	0928-0987, 1879-0720, 1879-0720
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!